Endocrine Metabolic & Immune Disorders-drug Targets

SCI SCIE

国际简称：ENDOCR METAB IMMUNE 参考译名：内分泌代谢和免疫疾病-药物靶点

主要研究方向：ENDOCRINOLOGY & METABOLISMIMMUNOLOGY-IMMUNOLOGY 非预警期刊

《内分泌代谢和免疫疾病-药物靶点》(Endocrine Metabolic & Immune Disorders-drug Targets)是一本由Bentham Science Publishers B.V.出版的以ENDOCRINOLOGY & METABOLISMIMMUNOLOGY-IMMUNOLOGY为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

4区中科院分区
Q3 JCR分区
69 年发文量
2 IF影响因子
未开放 是否OA
44 H-index
2001 创刊年份
6 issues/year 出版周期
English 出版语言

Aims & Scope

This journal is devoted to timely reviews and original articles of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Moreover, the topics related to effects of food components and/or nutraceuticals on the endocrine-metabolic-immune axis and on microbioma composition are welcome.

[ 查看全部 ]

投稿咨询加急咨询

Endocrine Metabolic & Immune Disorders-drug Targets期刊信息

ISSN：1871-5303
出版语言：English
是否OA：未开放
E-ISSN：2212-3873
出版地区：U ARAB EMIRATES
是否预警：否
出版商：Bentham Science Publishers B.V.
出版周期：6 issues/year
创刊时间：2001
开源占比：0
Gold OA文章占比：17.09%
OA被引用占比：0.0041...
出版国人文章占比：0.06
出版撤稿占比：0
研究类文章占比：71.01%

Endocrine Metabolic & Immune Disorders-drug Targets CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

4.1

0.552

0.555

学科类别	分区	排名	百分位
大类：Medicine 小类：Endocrinology, Diabetes and Metabolism	Q3	129 / 250	48%
大类：Medicine 小类：Immunology and Allergy	Q3	136 / 234	42%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Endocrine Metabolic & Immune Disorders-drug Targets中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	ENDOCRINOLOGY & METABOLISM 内分泌学与代谢 IMMUNOLOGY 免疫学 PHARMACOLOGY & PHARMACY 药学	4区 4区 4区

Endocrine Metabolic & Immune Disorders-drug Targets JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ENDOCRINOLOGY & METABOLISM	SCIE	Q4	152 / 198	23.5
学科：IMMUNOLOGY	SCIE	Q4	149 / 183	18.9
学科：PHARMACOLOGY & PHARMACY	SCIE	Q3	249 / 356	30.2
学科：ENDOCRINOLOGY & METABOLISM	SCIE	Q4	152 / 198	23.48
学科：IMMUNOLOGY	SCIE	Q4	144 / 183	21.58
学科：PHARMACOLOGY & PHARMACY	SCIE	Q3	266 / 356	25.42

Endocrine Metabolic & Immune Disorders-drug Targets历年数据统计

影响因子

中科院分区

Endocrine Metabolic & Immune Disorders-drug Targets中国学者发文选摘

1、Fortunellin Elevates the AMPK Pathway to Reduce Lipid Deposition and Immune Disorders in Young Non-Alcoholic Fatty Liver Disease Rat
Author: Ping, Nan; Qin, Na

Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303391165250828111133
2、The Emerging Role of tRNA-Derived Small RNAs (tsRNAs) in Radiation-Induced Cardiovascular Patholog
Author: Chen, Ying; Zhu, Yunjia; Qian, Lingmei; Hu, Qunchao

Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303460374260127095032
3、LGI1 Antibody-Associated Encephalitis Complicated with Sjögren's Syndrome and Acute Cerebral Infarction: A Case Report and Literature Revie
Author: Jiang, Dongxiao; Lian, Yanfen; Zhan, Xia; Wang, Jingjing; Xu, Pengjiao; Bi, Yuhua

Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303410062250729095927
4、From Limited Samples to Mechanistic Insights: Exploratory Identification and Functional Validation of a hsa_circ_0062400/hsa_circ_0002397-miR-338-3p-NRP1 Axis in Myasthenia Gravi
Author: Chen, Zhimin; Kong, Xiaotong; He, Ping; Na, Risu; Wang, Lihua

Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303446341260204093655
5、UBE2M Identified by CRISPR Screening as a Key Regulator of Cisplatin-Induced Acute Kidney Injury via the p53 Pathwa
Author: Yuan, Cheng; Chen, Feng; Gao, Xueyun; Yusufu, Ayinigaer; Lu, Danqin; Wu, Xiaoyan; Ni, Lihua

Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303410982251112055248
6、EphrinB2 Ameliorates Renal Fibrosis by Inhibiting the TGF-β/Smad3 Signaling Pathway and the Inflammation Respons
Author: Yuan, Cheng; Zhou, Qiuyuan; Chen, Feng; Gao, Xueyun; Yusufu, Ayinigaer; Wu, Xiaoyan; Ni, Lihua

Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303366454250507042518
7、Unlocking New Treatment Horizons for Celiac Disease: PRKCD Revealed as a Promising Target through Mendelian Randomizatio
Author: Zhou, Jie; Xu, Yixin; Wang, Haitao; Wang, Kun; Chen, Chao

Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303410531250815124524
8、Evaluation of the Space GlucoseControl System for Managing Stress-Induced Hyperglycemia in ICU Patients: Efficacy and Safety Assessmen
Author: Liu, Peng-Cheng; Fan, Dan-Dan; Bao, Qun-Ying; Jiang, Xiao-Mei; Lu, Juan

Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2026; Vol. 26, Issue , pp. -. DOI: 10.2174/0118715303346311250415111740